Active pharmaceutical ingredients (API) company MSN Labs, the parent company of Novadoz Pharmaceuticals, reported on Monday the receipt of US FDA approval to market Abiraterone Acetate 250mg tablets in 120 tablet count bottles for the treatment of prostate cancer with a steroid medication (prednisone or methylprednisolone).
This US FDA approval marks the ninth since March 2018, when Novadoz began commercial operations as MSN Labs' US sales and marketing affiliate for their finished dosage forms.The company expects additional product launches over the next 12 months continuing the organization's meteoric entrance and rise in the US market.
Additionally, the Abiraterone Acetate 250mg tablets is the second oncology product launched by Novadoz.
The company added that the Abiraterone Acetate 250mg tablets are the generic version of Janssen Pharmaceuticals' product Zytiga.
Lannett incurs lower net loss of USD7.6m for Q4 fiscal 2019
Innovent Biologics Inc partners with Shenogen Pharma Group Ltd for advanced cancer
Alvogen and Lotus Pharmaceuticals launch Vinorelbine in Europe
Lannett Company, Inc. names new chief financial officer
Acerus and Aytu Bioscience to Co-promote Natesto in the United States
Dr. Reddy's Laboratories Launches Pregabalin Capsules in the US Market
Pfizer to integrate Upjohn with Mylan to establish new global pharmaceutical company
Dr Reddy's Laboratories unveils Pregabalin Capsules in the US market
Baxter Wins US FDA Approval of Myxredlin, The First and Only Ready-To-Use Insulin for IV Infusion
Novadoz Pharmaceuticals awarded US FDA approval for generic Pregabalin capsules
Dr. Reddy's Laboratories Launches Ramelteon Tablets, in the US Market